Literature DB >> 3806375

Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals.

L B Sheiner.   

Abstract

This is the third in a series of tutorial articles discussing the analysis of pharmacokinetic data using parametric models. In this article the concern is how to test hypotheses about, and assign confidence intervals to, the values of the parameters of such models. The basic approach to both tasks involves determining the goodness of fit of the model to the data for alternative values of the parameters and using the change in goodness of fit to assess the plausibility of the alternative values. The goodness of fit is measured by the value of a (least-squares-type) objective function. An approximation to the dependence of the latter on the parameter values yields an estimate of the familiar asymptotic covariance matrix of the estimates. The latter can also be used to test hypotheses about, and assign confidence intervals to, functions of parameters.

Mesh:

Substances:

Year:  1986        PMID: 3806375     DOI: 10.1007/bf01059660

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

1.  A note on confidence intervals with extended least squares parameter estimates.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

2.  Parameter estimation for nonlinear models with emphasis on compartmental models.

Authors:  D M Allen
Journal:  Biometrics       Date:  1983-09       Impact factor: 2.571

3.  Analysis of pharmacokinetic data using parametric models--1: Regression models.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1984-02

4.  Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1985-10
  4 in total
  21 in total

1.  A double-site absorption model fits to pharmacokinetic data of repaglinide in man.

Authors:  X D Liu; H F Ji; L Xie; M Q Yan; L Zhang; X Huang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Apr-Jun       Impact factor: 2.441

2.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.

Authors:  Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

3.  The effect of sepsis upon gentamicin pharmacokinetics in neonates.

Authors:  M Lingvall; D Reith; R Broadbent
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 4.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

6.  A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Authors:  Thorsten Lehr; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Hans-Guenter Schaefer; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

8.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

Review 10.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.